Laura Zhu

Dr. Zhu is a seasoned biotech/pharmaceutical industry executive and entrepreneur with 25 years of experience that spans strategy, commercialization, new product planning, portfolio management, project management, business development and licensing. She has in-depth experience in evaluating assets and companies across a broad range of therapeutic indications.

​

Dr. Zhu co-founded LifeMax companies with primary responsibilities on licensing, corporate development, portfolio management and strategy.

​

Prior to LifeMax companies, Dr. Zhu established the new product planning and business development function for Impax's Brand Division. She successfully led the negotiation with AstraZeneca to in-license the US commercialization right for Zomig, a transformative transaction for Impax.

​

Prior to Impax, Dr. Zhu was with Eli Lilly wherein she held positions in new product planning and sales & marketing in the areas of psychiatric disorders and diabetes care.

​

Prior to Eli Lilly, Dr. Zhu was with Accenture as a strategy consultant for the biotech/pharmaceutical industry. Her clients included both startup and established pharmaceutical/biotech companies such as GSK, AstraZeneca and Genentech.

​

Dr. Zhu received her Ph.D. in Molecular Genetics from University of Pittsburgh and MBA from University of Chicago.